RESUMEN
We studied the influence of diclofenac on the pharmacokinetics of cloxacillin in healthy volunteers, 60 years or older, as well as the possible effect of cloxacillin and diclofenac on urinary protein excretion. In a randomized, double-blind, cross-over study 15 subjects were given 1 g cloxacillin, and placebo or 75 mg diclofenac, as single intravenous doses. Plasma concentrations of cloxacillin were followed over 10.5 hr, and urine excretion of cloxacillin over 24 hr. The effect of the drugs on urinary excretion of protein indicators of glomerular (albumin, IgG) and tubular (protein HC) function was also studied. Total plasma clearance of cloxacillin was with placebo 219 +/- 51 (mean +/- S.D.), and with diclofenac 212 +/- 39 ml/min./1.73 m2 (ns); renal clearance was 97 +/- 21 and 96 +/- 24 ml/min./1.73 m2, respectively (ns). The terminal t1/2 of cloxacillin was 1.03 +/- 0.42 hr with placebo, and 1.12 +/- 0.37 with diclofenac (ns). The mean ratio of AUC0-infinity's (cloxacillin plus diclofenac/cloxacillin plus placebo) was 1.03 (90% CI: 0.99, 1.08). Urinary excretion of the proteins was low and was not increased by cloxacillin or diclofenac. In healthy volunteers, 60 years or older, diclofenac does not alter cloxacillin pharmacokinetics, and neither cloxacillin nor diclofenac in single intravenous doses cause renal dysfunction.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Cloxacilina/farmacocinética , Diclofenaco/farmacología , Penicilinas/farmacocinética , Anciano , Anciano de 80 o más Años , Albuminuria , Cloxacilina/sangre , Creatinina/orina , Estudios Cruzados , Método Doble Ciego , Femenino , Humanos , Riñón/efectos de los fármacos , Masculino , Persona de Mediana Edad , Penicilinas/sangre , Proteínas/efectos de los fármacos , Proteínas/metabolismo , Factores de TiempoRESUMEN
Antinociception by nonsteroidal antiinflammatory drugs, notably diclofenac and S(+)-ibuprofen, has traditionally been attributed to peripheral tissue cyclooxygenase inhibition. This study investigates the potential role of the nitric oxide system for the central antinociceptive effects of diclofenac, S(+)-, and R(-)-ibuprofen. Diclofenac and S(+)- but not R(-)-ibuprofen inhibited the behavioral response dose dependently, "biting, scratching, and licking (BSL)," induced by the spinal application of N-methyl-D-aspartate, but not that of amino-methylisoxazole-propionic acid or substance P. Diclofenac and S(+)-ibuprofen induced a parallel shift in the number of BSL responses and in the duration of the response in the behavioral model at their approximate median effective doses (diclofenac 1 mumol and S(+)-ibuprofen 5 mumol). Pretreatment with L-arginine, the natural substrate for the nitric oxide synthetase, antagonized diclofenac, and S(+)-ibuprofen-induced suppression of the biting, scratching, and licking response evoked by intrathecal N-methyl-D-aspartate. D-arginine did not antagonize the diclofenac- and S(+)-ibuprofen-induced antinociception. The study results indicate that analgesia after diclofenac and S(+)-ibuprofen involves a central mechanism which may add to the peripheral antinociceptive effect of these agents. The central action of diclofenac and S(+)-ibuprofen is partly mediated by an interaction with the N-methyl-D-aspartate receptor and nitric oxide-generating mechanisms.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Conducta Animal/efectos de los fármacos , N-Metilaspartato/farmacología , Sustancia P/farmacología , Ácido alfa-Amino-3-hidroxi-5-metil-4-isoxazol Propiónico/farmacología , Animales , Diclofenaco/farmacología , Ibuprofeno/farmacología , Masculino , N-Metilaspartato/administración & dosificación , Ratas , Ratas Sprague-Dawley , Estereoisomerismo , Sustancia P/administración & dosificación , Ácido alfa-Amino-3-hidroxi-5-metil-4-isoxazol Propiónico/administración & dosificaciónRESUMEN
BACKGROUND: These studies were undertaken to investigate the site and nature of the antinociceptive effect of NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) and paracetamol in the central nervous system (CNS). METHODS: Different nociceptive test models were employed: the tail-flick and hot-plate tests (thermoreceptors), the writhing test (visceral chemoreceptors) the "scratching, biting, licking" (SBL) behaviour and the colorectal distension test (mechanoreceptors). Drugs were given intraperitoneally (i.p.), intracerebroventricularly (i.c.v.), intrathecally (i.t.) or as local injection via cannulae implanted stereotactically. Nerve destruction was made by local injection of the neurotoxin 5,7-dihydroxytryptamine (5,7-DHT). Whole brain and spinal cord contents of serotonin and 5-hydroxyindole acetic acid (5-HIAA) were analysed by high pressure liquid chromatography (HPLC). RESULTS: Injections of diclofenac induced antinociception in visceral pain models (writhing test, colorectal distension test), but not in two models of somatosensory pain (tail-flick and hot-plate test). The antinociceptive effect of diclofenac (i.p., i.c.v., or i.t.) was reversed by i.p. naloxone. Naloxone also reversed the effect of diclofenac injected locally into thalamic and hypothalamic areas involved in pain transmission as well as in n. paragigantocellularis or n. raphe magnus. In addition, chemical destruction of the n. raphe region attenuated the antinociceptive effect of diclofenac. Inhibition of serotonergic transmission by pretreatment with methiothepin, ritanserin, parachlorophenylalanine (PCPA) or 5,7-DHT also reduced the antinociceptive effect of diclofenac in a visceral pain model. Pretreatment with diclofenac or ibuprofen blocked pain behaviour (SBL) after activation of excitatory amino acid receptors of the NMDA type, but not pain behaviour after activation of AMPA or substance P (SP) receptors. Paracetamol inhibited hyperalgesia after both NMDA and SP. The antinociceptive effects of diclofenac, ibuprofen and paracetamol were reversed by L-arginine, but not by D-arginine. CONCLUSIONS: The antinociceptive effect of diclofenac involves a central nervous component which may be elicited from several defined areas in the CNS. Part of the antinociceptive effect seems to be mediated by descending inhibitory opioid, serotonin and/or other neurotransmitter systems interfering with visceral pain impulse traffic at the spinal level. NSAIDs and paracetamol interfere with nociception associated with spinal NMDA receptor activation. This effect involves an inhibitory action on spinal nitric oxide (NO) mechanisms. Possibly, the supraspinal antinociceptive effect of NSAIDs may be explained by an analogous action.
Asunto(s)
Acetaminofén/farmacología , Antiinflamatorios no Esteroideos/farmacología , Encéfalo/efectos de los fármacos , Nociceptores/efectos de los fármacos , Médula Espinal/efectos de los fármacos , Acetaminofén/administración & dosificación , Acetaminofén/antagonistas & inhibidores , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/antagonistas & inhibidores , Arginina/farmacología , Conducta Animal/efectos de los fármacos , Células Quimiorreceptoras/efectos de los fármacos , Diclofenaco/administración & dosificación , Diclofenaco/antagonistas & inhibidores , Diclofenaco/farmacología , Ibuprofeno/administración & dosificación , Ibuprofeno/antagonistas & inhibidores , Ibuprofeno/farmacología , Masculino , Mecanorreceptores/efectos de los fármacos , Naloxona/administración & dosificación , Naloxona/farmacología , Dolor/fisiopatología , Dolor/prevención & control , Ratas , Ratas Sprague-Dawley , Receptores AMPA/efectos de los fármacos , Receptores de N-Metil-D-Aspartato/efectos de los fármacos , Receptores de Neuroquinina-1/efectos de los fármacos , Receptores de Serotonina/efectos de los fármacos , Termorreceptores/efectos de los fármacosRESUMEN
The hypothesis tested was that inhibition of the L-arginine-nitric oxide (NO) pathway may represent a potential central mechanism of action for acetaminophen (paracetamol). Spinal administration of N-methyl-D-aspartate (NMDA, 0.5 nmol), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA, 0.1 nmol) or substance P (SP, 0.5 nmol) to the rat provoked a specific behaviour characterized by biting, scratching and licking (BSL). This behaviour was antagonized by pretreatment with acetaminophen for NMDA and SP but not for AMPA. Further, the antinociceptive effect of acetaminophen was readily reversed by administration of the natural substrate for nitric oxide synthase (NOS), L-arginine, but not by D-arginine. This suggests that the analgesic effect of acetaminophen is related to inhibition of NO generation. Potential mechanisms for this may involve NMDA and SP. Our data suggest that a significant portion of the analgesic effect of acetaminophen, when used clinically, may be related to an interaction with the central nervous system L-arginine-NO pathway.
Asunto(s)
Acetaminofén/farmacología , Hiperalgesia/inducido químicamente , Hiperalgesia/fisiopatología , N-Metilaspartato , Enfermedades de la Médula Espinal/inducido químicamente , Sustancia P , Acetaminofén/antagonistas & inhibidores , Animales , Arginina/química , Arginina/farmacología , Conducta Animal/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Inyecciones Espinales , Nociceptores/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Enfermedades de la Médula Espinal/fisiopatología , Ácido alfa-Amino-3-hidroxi-5-metil-4-isoxazol PropiónicoRESUMEN
The effect of diclofenac on pain after arthroscopy of the knee joint was investigated in 64 patients. The aim of this double-blind, placebo-controlled, randomised study was to compare administration before surgery with delayed treatment. The effect on postoperative pain was evaluated by means of a Visual Analogue Scale and recording of the need for additional analgesics postoperatively. After surgery, hourly assessments were performed within 6 h after the anaesthetic block (approximately 5 h after start of surgery), and on the morning after surgery. Both treatment with diclofenac before surgery and delayed treatment were superior to placebo concerning pain scores within 6 h after onset of anaesthesia (P < 0.0065 and P < 0.0005, respectively). On the morning after surgery, only delayed treatment was superior to placebo (P < 0.02). No differences in pain scores were evident between the different groups treated with diclofenac. No differences in the need for additional analgesics were found.
Asunto(s)
Diclofenaco/uso terapéutico , Articulación de la Rodilla , Dolor/prevención & control , Artroscopía/efectos adversos , Método Doble Ciego , Femenino , Humanos , Masculino , Dolor/etiología , Factores de TiempoRESUMEN
The putative central analgesic activity of diclofenac was investigated in a human experimental pain model using intraneural electrical stimulation in the median nerve. Since pain is induced proximal to the peripheral nociceptors, the model can be used to test central analgesic properties of i.a. pharmacological interventions performed during series of repeated stimulations. A single intravenous dose of 50 mg diclofenac or saline was administered during an ongoing series of painful intraneural stimulations in a double-blind cross-over study in 10 healthy volunteers. Neither diclofenac nor saline caused any significant change in the level of pain experienced during stimulation. Thus, no central analgesic effect of diclofenac could be demonstrated in this model. The stability of individual visual analogue scale (VAS) scores throughout the experimental sessions, also after administration of the potent peripheral analgesic agent diclofenac, underlines the validity of intraneural stimulation as a central pain model in humans.
Asunto(s)
Diclofenaco/uso terapéutico , Dolor/tratamiento farmacológico , Adolescente , Adulto , Diclofenaco/efectos adversos , Método Doble Ciego , Estimulación Eléctrica , Electrofisiología , Femenino , Humanos , Flujometría por Láser-Doppler , Masculino , Nervio Mediano , Persona de Mediana Edad , Naloxona/farmacología , Dimensión del Dolor , Flujo Sanguíneo Regional/efectos de los fármacos , Piel/irrigación sanguíneaRESUMEN
The aim of the present study was to assess the efficacy and tolerability of single oral doses of 50 mg and 100 mg of diclofenac-K compared to placebo in migraine sufferers during three attacks. The study was conducted in a double-blind, randomized, placebo-controlled, three-period, within-patient comparative trial; 72 migraine patients were treated with diclofenac-K (50 mg or 100 mg) or placebo at six centres (1 in Sweden and 5 in Finland). The primary efficacy end-point was the change in pain intensity assessed on a 100 mm Visual Analogue Scale (VAS) at 120 min after taking the study medication. We found that 50 mg and 100 mg of diclofenac-K reduced the pain intensity significantly better than placebo (p = 0.003 and p = 0.001, respectively), without difference between the doses; 100 mg diclofenac-K was significantly better than placebo in improving phonophobia, photophobia, working ability and need for rescue medication. Diclofenac-K 50 mg or 100 mg is an effective and well-tolerated acute treatment for migraine headache and its associated symptoms. The higher dose of diclofenac-K was only marginally more effective than the lower dose.
Asunto(s)
Diclofenaco/administración & dosificación , Trastornos Migrañosos/tratamiento farmacológico , Adolescente , Adulto , Anciano , Diclofenaco/efectos adversos , Diclofenaco/uso terapéutico , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastornos Migrañosos/complicaciones , Trastornos Migrañosos/fisiopatología , Dimensión del Dolor/métodos , Satisfacción del Paciente , Placebos , Encuestas y CuestionariosRESUMEN
The effectiveness of diclofenac 50 mg t.i.d. as additive treatment to parenteral patient-controlled administration therapy (PCAT) with morphine in cancer pain has been investigated in a double-blind study. In the fifteen patients who completed the study, morphine i.v. was titrated to optimal pain relief over 5 days. The mean total morphine consumption was significantly reduced during diclofenac administration (82.8 mg morphine per day) compared to placebo (95.0 mg morphine per day). The reduction in mean morphine consumption during active treatment with diclofenac was independent of the initial dose of self-titrated morphine. Pain, self-assessed according to VAS, tended to be lower during the diclofenac period, although the difference did not reach statistical significance. No adverse events were recorded among the 15 patients who completed the study. The present findings show that a non-steroidal anti-inflammatory agent, such as diclofenac, has a morphine-sparing effect in morphine-treated patients with cancer pain.
Asunto(s)
Diclofenaco/uso terapéutico , Morfina/uso terapéutico , Neoplasias/fisiopatología , Dolor/tratamiento farmacológico , Adulto , Anciano , Analgesia Controlada por el Paciente , Diclofenaco/administración & dosificación , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Morfina/administración & dosificaciónRESUMEN
The ethacrynic acid-induced writhing response (WR) in the rat was studied after microinjections of diclofenac 0.1 ng-1 microgram/0.5 microliter (0.32 pmol to 3.2 nmol) into several brain regions involved in control of nociceptive behavior. The WR was inhibited after injections into the periaqueductal grey matter (PAG), ventromedial thalamus (VM), medial preoptic area (MPA) and the nucleus raphe magnus (NRM). Morphine 50 ng/0.5 microliter (0.16 nmol) was used as a positive control and vehicle injections were performed as negative reference. After diclofenac, there was a dose-dependent reduction of the WR with a threshold dose of approximately 1-10 ng in all brain areas studied except the nucleus reticularis paragigantocellularis interna (NRPGi). Naloxone 50 ng/0.5 microliter (0.15 nmol) administered into the same site 30 min after diclofenac injection, antagonized the diclofenac-induced inhibition of the WR almost completely in PAG and VM. Previous results demonstrate a central, naloxone-reversible component in the analgetic action of diclofenac. A qualitatively similar, centrally induced inhibition of the WR may be elicited after injections into PAG, VM and NRM. Thus, in addition to its peripheral mechanism of action, the non-steroidal anti-inflammatory drug, diclofenac, has a central mechanism of action which directly or indirectly involves a central opioid component.
Asunto(s)
Encéfalo/efectos de los fármacos , Diclofenaco/farmacología , Dolor/fisiopatología , Animales , Modelos Animales de Enfermedad , Masculino , Microinyecciones , Sustancia Gris Periacueductal/efectos de los fármacos , Área Preóptica/efectos de los fármacos , Núcleos del Rafe/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Tálamo/efectos de los fármacosRESUMEN
Diclofenac sodium suppositories 150-200 mg day-1 were compared with placebo in a double-blind study during the first 3 days after uvulopalatopharyngoplasty in 40 patients with habitual snoring or obstructive sleep apnoea syndrome. Consumption of rescue analgesics (paracetamol suppositories) and pain assessed by a visual analogue scale were significantly less in the diclofenac group. Bleeding time (modified Ivy's test) and reported side effects did not differ between the two groups.
Asunto(s)
Diclofenaco/uso terapéutico , Dolor Postoperatorio/tratamiento farmacológico , Hueso Paladar/cirugía , Faringe/cirugía , Úvula/cirugía , Acetaminofén/uso terapéutico , Adulto , Tiempo de Sangría , Diclofenaco/efectos adversos , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Dimensión del Dolor , Síndromes de la Apnea del Sueño/cirugía , Ronquido/cirugíaRESUMEN
The efficacy and tolerability of diclofenac suppositories given pre and/or post-operatively were investigated in a randomized double-blind study on 99 patients undergoing tonsillectomy. In one group, 50 mg diclofenac was given 1 h preoperatively, followed by 50 mg directly after the operation. In another group, diclofenac 100 mg was given only immediately post-operatively. A significantly lower consumption of rescue analgesics (paracetamol and/or pethidine) was found in the group treated preoperatively with diclofenac and the average time until first demand of rescue analgesics was significantly longer compared to the group given diclofenac post-operatively only. The tolerance was good and no serious bleeding complications occurred in either group. In the treatment of post-operative pain after tonsillectomy, the combination of pre and post-operative administration of diclofenac suppositories resulted in significantly lower consumption of rescue analgesics and is thus preferable to administration solely post-operatively.
Asunto(s)
Analgesia , Diclofenaco/uso terapéutico , Dolor Postoperatorio/prevención & control , Premedicación , Tonsilectomía , Acetaminofén/administración & dosificación , Acetaminofén/uso terapéutico , Adolescente , Adulto , Diclofenaco/administración & dosificación , Diclofenaco/efectos adversos , Método Doble Ciego , Femenino , Humanos , Masculino , Meperidina/administración & dosificación , Meperidina/uso terapéutico , Persona de Mediana Edad , Placebos , Cuidados Posoperatorios , Supositorios , Tonsilectomía/efectos adversosRESUMEN
Morphine and its major metabolites, morphine-3-glucuronide and morphine-6-glucuronide, were given intracerebroventricularly (i.c.v.) to rats. The antinociceptive effects were assessed in the tail-flick and hot-plate tests as well as the writhing test. Ventilatory effects were studied in halothane-anaesthetized rats. Based on calculated ED50 values, morphine-6-glucuronide was approximately 200 times more potent that morphine itself in the tail-flick and hot-plate tests. In the writhing test the difference in ED50 was approximately 9-fold. Morphine and morphine-6-glucuronide administered i.c.v. induced dose-related decreases in minute ventilation in the dose range 2.7 x 10(-9)-1.3 x 10(-7) mol. The dose-response curve for minute ventilation was steeper for morphine-6-glucuronide than for morphine. Morphine-6-glucuronide was approximately 10 times more potent than morphine in depressing minute ventilation. Morphine-6-glucuronide reduced both tidal volume and respiratory frequency, while morphine reduced only the tidal volume. Morphine-3-glucuronide, in contrast, increased both tidal volume and respiratory frequency, causing an increase in minute ventilation. Apnoea was elicited after the highest doses of morphine-6-glucuronide but not of morphine. The potency difference for depression of minute ventilation between morphine-6-glucuronide and morphine corresponded well to the difference in the writhing test but not to the potency difference in the tail-flick or hot-plate tests. The ventilatory depression induced by morphine and morphine-6-glucuronide was readily reversed by naloxone, while the hyperventilation caused by morphine-3-glucuronide was slightly potentiated by the opioid antagonist. Naloxone pretreatment completely blocked the ventilatory depression induced by morphine-6-glucuronide. These results show that the potent ventilatory depression induced by morphine-6-glucuronide is related to its antinociceptive effects in rats. Furthermore, the fact that morphine-3-glucuronide stimulated ventilation and that morphine had a more shallow ventilatory dose-response curve compared to morphine-6-glucuronide may indicate that morphine-3-glucuronide is a functional antagonist of the depressive effects of morphine and morphine-6-glucuronide on ventilation.
Asunto(s)
Analgésicos , Derivados de la Morfina/farmacología , Respiración/efectos de los fármacos , Animales , Relación Dosis-Respuesta a Droga , Inyecciones Intraventriculares , Masculino , Naloxona/farmacología , Ratas , Ratas Endogámicas , Tiempo de Reacción/efectos de los fármacosRESUMEN
The antinociceptive effect of subcutaneously (s.c.), intracerebroventricularly (i.c.v.) or intrathecally (i.t.) administered diclofenac was studied in a series of experiments employing the tail-flick (0.01-10.0 mg/kg body weight i.p., 1-50 micrograms i.c.v., 1-10 micrograms i.t.) and hot-plate (0.01-50 mg/kg body weight i.p., 1-50 micrograms i.c.v., 1-10 micrograms i.t.) models representing somatosensory stimuli and the writhing test (0.001 mg-10 mg s.c., 0.1-200 micrograms i.c.v., 0.1-100 micrograms i.t.) and colorectal distension (1-200 micrograms i.c.v.) models representing noxious visceral stimuli. Diclofenac did not exert any antinociceptive effects in the tail-flick or hot-plate models. In the writhing test, diclofenac dose-dependently inhibited the number of writhings after s.c. administration (0.001-10.0 mg/kg body weight) with an ED50 of 1 mg/kg. A similar dose-dependent action of diclofenac was seen after i.c.v. (0.1-200 micrograms) and i.t. (0.1-100 micrograms) administration with an ED50 of 3 micrograms in both cases. The antinociceptive effect of diclofenac administered s.c., i.c.v. or i.t. was almost completely reversed by pretreatment with naloxone, (1 mg/kg body weight s.c.). In the colorectal distension model, the i.c.v. administration of diclofenac (1-200 micrograms), which attenuated the cardiovascular response to colorectal distension, was reversed by naloxone. The pressor and tachycardia response to a 20 s, 80 mmHg colorectal distension was inhibited by diclofenac 100 micrograms i.c.v. (16.1 +/- 1.7 mmHg or 58% and 39.4 +/- 0.4 bpm or 70% versus control, respectively). It is concluded that diclofenac exerts a central, naloxone-reversible antinociceptive action in experimental animals after noxious visceral stimuli but not after somatosensory stimuli.